Abstract:Cancer remains a lethal threat to global lives. Development of novel anticancer therapeutics is still a challenge to scientists in the field of biomedicine. In cancer cells, the metabolic features are significantly different from those of normal ones, which are hallmarks of several malignancies. Recent studies brought atypical cellular metabolism, such as aerobic glycolysis or the Warburg effect, into the scientific limelight. Targeting these altered metabolic pathways in cancer cells presents a promising therapeutic strategy. Pyruvate dehydrogenase kinases (PDKs), key enzymes in the pathway of glucose metabolism, could inactivate the pyruvate dehydrogenase complex (PDC) by phosphorylating it and preserving the substrates pyruvate, lactate and alanine for gluconeogenesis. Overexpression of PDKs could block the oxidative decarboxylation of pyruvate to satisfy high oxygen demand in cancer cells, while inhibition of PDKs could upregulate the activity of PDC and rectify the balance between the demand and supply of oxygen, which could lead to cancer cell death. Thus, inhibitors targeting PDKs represent a promising strategy for cancer treatment by acting on glycolytic tumors while showing minimal side effects on the oxidative healthy organs. This review considers the role of PDKs as regulator of PDC that catalyzes the oxidative decarboxylation of pyruvate in mitochondrion. It is concluded that PDKs are solid therapeutic targets. Inhibition of PDKs could be an attractive therapeutic approach for the development of anti-cancer drugs.

Development of pyruvate dehydrogenase kinase inhibitors in medicinal chemistry with particular emphasis as anticancer agents.

Recent advances in pyruvate dehydrogenase kinase inhibitors: Structures, inhibitory mechanisms and biological activities

Development of Dichloroacetamide Pyrimidines As Pyruvate Dehydrogenase Kinase Inhibitors to Reduce Cancer Cell Growth: Synthesis and Biological Evaluation

Targeting Tumor Metabolism for Cancer Treatment: is Pyruvate Dehydrogenase Kinases (pdks) a Viable Anticancer Target?

Reprogramming Energy Metabolism with Synthesized PDK Inhibitors Based on Dichloroacetate Derivatives and Targeted Delivery Systems for Enhanced Cancer Therapy

Dichloroacetophenones targeting at pyruvate dehydrogenase kinase 1 with improved selectivity and antiproliferative activity: Synthesis and structure-activity relationships.

Synthesis, biological evaluation and structure-activity relationship of novel dichloroacetophenones targeting pyruvate dehydrogenase kinases with potent anticancer activity

Synthesis and Biological Evaluation of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides As Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors to Reduce the Growth of Cancer Cells

Anticancer effects of some novel dichloroacetophenones through the inhibition of pyruvate dehydrogenase kinase 1

Targeting the Pyruvate Dehydrogenase Complex/pyruvate Dehydrogenase Kinase (PDC/PDK) Axis to Discover Potent PDK Inhibitors Through Structure-Based Virtual Screening and Pharmacological Evaluation.

Computational Study on New Natural Compound Inhibitors of Pyruvate Dehydrogenase Kinases

Novel Dichloroacetophenone-Based PDHK1 Inhibitors as Potent Anticancer Agents

Unexpected Discovery of Dichloroacetate Derived Adenosine Triphosphate Competitors Targeting Pyruvate Dehydrogenase Kinase to Inhibit Cancer Proliferation.

High-throughput Screening of Novel Pyruvate Dehydrogenase Kinases Inhibitors and Biological Evaluation of Their in Vitro and in Vivo Antiproliferative Activity.

Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors

Pyrrolo[2,3-d]pyrimidines as potential kinase inhibitors in cancer drug discovery: A critical review

Rational Design of Mitochondria-Targeted Pyruvate Dehydrogenase Kinase 1 Inhibitors with Improved Selectivity and Antiproliferative Activity.

Recent Advances on PKM2 Inhibitors and Activators in Cancer Applications.

Structure-Activity Relationship of Substituted Pyrazoline Derivatives as Small Molecule Tyrosine Kinase Inhibitors